Meaningful
Clinical Results
Review key efficacy endpoints from the TIBSOVO AML clinical trials, including survival, response, and remission data.1
See EfficacyTest
to Inform
A positive IDH1 mutation test can help guide the next treatment decision for appropriate patients with AML.1
Target mIDH1NCCN Guidelines®
Recommendation
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommends ivosidenib (TIBSOVO) + AZA as an NCCN category 1 preferred treatment option for newly diagnosed patients ≥18 years of age with mIDH1 AML who are not candidates for intensive remission induction therapy.4
ViewRecommendations